Antonio R. Moreira, PhD

University of Maryland
Vice Provost, Academic Affairs
Antonio (Tony) R. Moreira, PhD is Vice Provost for Academic Affairs at the University of Maryland, Baltimore County (UMBC) and is responsible for academic affairs matters within the Provost’s Office. In addition to his administrative responsibilities, he has maintained an active teaching and research program in bioprocessing, regulatory science and engineering. He frequently presents short courses in biotechnology topics for industry as well as regulatory agencies. Dr. Moreira has over 30 years’ experience in the biopharma sector and spent nearly 10 years in management positions in the private sector with International Flavors and Fragrances and with Schering-Plough Corp. (now Merck). He has been an ISPE Member for over 20 years, is currently Chair of the Board of the ISPE Foundation, and is the founding President of the ISPE Chesapeake Bay Area Chapter. He has been a member of the International Board of Directors of ISPE. He has also been active in the Parenteral Drug Association, Biotechnology Industry Organization (Chairman of the Council of Biotechnology Centers), American Chemical Society and American Institute of Chemical Engineers.

He is published in many peer-reviewed publications, is a co-editor for several books and is a frequent speaker at national and international conferences. Dr. Moreira holds a BS in Chemical Engineering from the University of Oporto, an MS and PhD in Chemical and Biochemical Engineering from the University of Pennsylvania.

Related Articles

Figure 2: Setting a risk-based CQV plan
Features
Today’s Pharma and Biotech Projects: A Phased Approach

This article revisits the concept of phased engineering, procurement, and construction (EPC) and updates it with risk-based considerations specifically regarding the commissioning, qualification, and validation (CQV) of general life-cycle principles for pharma and biotech projects. Enhancing the relationship between phases of a project, advanced planning, and more formal management of...

Opportunities in Continuous Manufacturing of Large Molecules
Features
Opportunities in Continuous Manufacturing of Large Molecules

Continuous manufacturing has attracted significant interest over the past decade for small molecules formulated as drug products. The case for adopting continuous manufacturing platforms for manufacturing biologics (i.e., large proteins or biologic products such as vaccines) would, in principle, be even more justified for both quality and business gains. This article briefly reviews continuous...

Quality & Regulatory Solutions for PAT in Continuous Manufacturing
Technical
Quality & Regulatory Solutions for PAT in Continuous Manufacturing

Process analytical technology (PAT) is perceived as the main enabler for a robust control strategy with continuous manufacturing (CM) because process analytical technology can aid in implementing continuous manufacturing throughout the entire life cycle. This article discusses quality and regulatory hurdles in the life cycle of a process analytical technology application—including model...